Why are ovaries not recommended to be removed after estrogen-driven breast cancer, versus starting on hormonal blockers?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 19, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Ovaries are not recommended to be removed after estrogen-driven breast cancer, and instead, hormonal blockers such as tamoxifen or aromatase inhibitors are preferred due to their effectiveness in blocking estrogen's effects without the surgical risks and permanent menopausal symptoms associated with oophorectomy. For premenopausal women, tamoxifen (typically 20mg daily for 5-10 years) is the standard treatment, working by blocking estrogen receptors in breast tissue 1. The optimal duration of ovarian suppression is 5 years, as supported by the SOFT and TEXT trials, which showed that ovarian suppression plus tamoxifen or an aromatase inhibitor improved disease-free survival compared to tamoxifen alone 1.

Some key points to consider when deciding on ovarian suppression include:

  • The patient's risk of recurrence, with higher-risk patients benefiting more from ovarian suppression 1
  • The potential side effects of ovarian suppression, including menopausal symptoms and bone loss 1
  • The importance of preserving ovarian function, especially in younger women who may want to preserve fertility options 1

The American Society of Clinical Oncology recommends that higher-risk patients receive ovarian suppression in addition to adjuvant endocrine therapy, whereas lower-risk patients should not 1. The standard duration of ovarian suppression is 5 years, and the preferred method of administration is monthly GnRH agonist therapy 1.

Overall, the decision to use hormonal blockers instead of removing the ovaries should be based on the individual patient's risk factors, medical history, and personal preferences, with the goal of minimizing morbidity, mortality, and improving quality of life 1.

From the FDA Drug Label

The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis.

The ovaries are not recommended to be removed after estrogen-driven breast cancer, versus starting on hormonal blockers, because hormonal blockers like letrozole can effectively decrease estrogen levels without the need for surgical removal of the ovaries.

  • Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system, which inhibits the conversion of androgens to estrogens.
  • Ovariectomy is not necessary as letrozole can achieve similar effects in reducing estrogen levels, and it does not lead to an increase in serum FSH.
  • Letrozole selectively inhibits gonadal steroidogenesis without affecting adrenal mineralocorticoid or glucocorticoid synthesis, making it a safer alternative to ovariectomy 2.

From the Research

Ovaries Removal vs Hormonal Blockers in Estrogen-Driven Breast Cancer

  • The decision to remove ovaries or start hormonal blockers in patients with estrogen-driven breast cancer depends on various factors, including the patient's menopausal status, tumor characteristics, and overall health.
  • Studies have shown that ovarian suppression or ablation can be an effective treatment for premenopausal women with estrogen receptor-positive breast cancer 3, 4.
  • However, removing ovaries is not always recommended, as it can lead to premature menopause and its associated symptoms, such as hot flashes, vaginal dryness, and osteoporosis.
  • Hormonal blockers, such as tamoxifen and aromatase inhibitors, can be used to reduce estrogen levels and prevent cancer recurrence 3, 5.
  • Research has shown that aromatase inhibitors can be more effective than tamoxifen in reducing breast cancer recurrence in premenopausal women with ovarian suppression 3.
  • The combination of goserelin and tamoxifen has been shown to reduce the risk of recurrence in endocrine-responsive premenopausal breast cancer, but the combination is not superior to either modality alone 4.

Considerations for Treatment

  • The patient's quality of life and menopausal symptoms should be taken into account when deciding between ovaries removal and hormonal blockers.
  • Alternative treatments, such as vitamin E, clonidine, and selective serotonin reuptake inhibitor antidepressants, can be used to manage menopausal symptoms 6.
  • The risk of breast cancer recurrence and mortality should be carefully weighed against the potential benefits and risks of each treatment option.
  • Ongoing research is needed to determine the optimal treatment strategy for patients with estrogen-driven breast cancer, including the use of new drugs targeting molecular pathways involved in endocrine resistance 5.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What are the risks of using estrogen cream in patients with a history of breast cancer?
Is estrogen therapy safe for patients with a history of breast cancer?
What is the treatment plan for a 52-year-old female (F) with a low estradiol level?
What is the best approach to manage menopausal symptoms in a postmenopausal woman with low estradiol, high FSH, and low progesterone levels?
What treatment options are available for a postmenopausal woman with low estradiol levels, hypogonadism (testosterone total 23, testosterone free 2.5), and symptoms potentially related to menopause?
How to manage a 75-year-old male with schizophrenia, neurocognitive disorder, and senile dementia, on olanzapine and Effexor, with recent rib fractures and suicidal comments?
What is the role of cryoprecipitates (cryoprecipitated antihemophilic factor) in trauma patients with significant bleeding and low fibrinogen levels?
What is the role of cryoprecipitate (cryoprecipitated antihemophilic factor) in managing significant bleeding with low fibrinogen levels?
Is starting Meclizine 12.5 mg TID PRN reasonable for managing dizziness in a patient with schizophrenia, neurocognitive disorder, senile dementia, and recent rib fractures, who is taking olanzapine and Effexor?
What does an elevation of free kappa light chain proteins indicate?
How to manage hypotension?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question